Ram Chuttani
About Ram Chuttani
Ram Chuttani, M.B., B.S., is Allurion Technologies’ Chief Medical Officer and a founder, serving since November 2017. He is 64 years old, educated at Maulana Azad Medical College, and completed his internal medicine residency at Norwalk Hospital (Yale) and a gastroenterology fellowship at Harvard Medical School . Prior to Allurion, he was Director of Endoscopy and Chief of Interventional Gastroenterology at Beth Israel Deaconess Medical Center and served on the Harvard Medical School faculty for 20 years; he has published over 100 scientific articles and lectured widely on advanced endoscopic procedures, co‑inventing treatments for GERD and co‑developing novel obesity therapies . Company or role‑specific TSR, revenue growth, and EBITDA growth metrics are not disclosed in the filings reviewed .
Past Roles
| Organization | Role | Years | Strategic Impact |
|---|---|---|---|
| Allurion Technologies, Inc. (ALUR) | Founder; Chief Medical Officer | Since Nov 2017 | Clinical leadership for development of obesity treatments including Allurion Balloon; co‑development of novel treatment approaches |
| Beth Israel Deaconess Medical Center | Director of Endoscopy; Chief, Interventional Gastroenterology | Not disclosed | Led advanced endoscopic procedures; pioneered innovative therapies in digestive disease care |
| Harvard Medical School | Faculty | 20 years | Research and teaching; >100 scientific publications; global lectures on advanced endoscopy |
External Roles
| Organization | Role | Years | Notable Contributions |
|---|---|---|---|
| Harvard Medical School | Faculty | 20 years | Published 100+ scientific articles; lectured and demonstrated novel/advanced endoscopic procedures globally |
Fixed Compensation
- Not disclosed. Ram Chuttani is not listed as a Named Executive Officer (NEO) in the 2023 or 2024 compensation tables; those tables cover the CEO, CFO (2023) and CEO, Chief Legal Officer, and COO (2024) .
Performance Compensation
- Not disclosed. The company’s annual performance cash bonus framework is described for NEOs, but no individual metrics or payouts are disclosed for Ram Chuttani in 2023–2024 proxies .
Equity Ownership & Alignment
| Metric | As of Feb 28, 2025 | As of Oct 31, 2025 |
|---|---|---|
| Shares owned (direct/indirect) | 66,516 | 66,516 |
| Options exercisable within 60 days | 7,433 | 15,597 |
| Total beneficial shares (shares + exercisable options) | 73,949 | 82,113 |
| Shares outstanding (company) | 5,961,714 | 7,770,047 |
| Beneficial ownership % | 1.24% (73,949 ÷ 5,961,714) | 1.06% (82,113 ÷ 7,770,047) |
- Alignment safeguards: Allurion’s Insider Trading Policy prohibits pledging company stock as collateral and hedging transactions by directors and officers, improving alignment and lowering hedging/pledging risk .
- Clawback: The company adopted a Compensation Recovery Policy effective October 2, 2023 requiring recovery of erroneously awarded compensation to current/former executive officers upon material restatements, subject to SEC/NYSE rules .
Employment Terms
- Specific employment agreement terms, severance, non‑compete, and change‑of‑control economics for Ram Chuttani are not disclosed in the filings reviewed .
- Company‑wide governance context: filings affirm no material legal proceedings involving directors or executive officers, which includes Ram Chuttani .
Investment Implications
- Strong clinical leadership and founder status: Chuttani’s long tenure and deep endoscopy expertise support product execution and clinical credibility, a lever for adoption and regulatory progress .
- Skin‑in‑the‑game: His beneficial ownership shows alignment, and company policy prohibits pledging/hedging, reducing adverse incentive risks .
- Disclosure gaps: Lack of individual compensation detail (fixed/variable targets, vesting) limits pay‑for‑performance analysis on a standalone basis .
- Capital structure and governance backdrop: RTW’s large stake (32.7%) and multiple capital proposals (warrant repricing and note conversions) increase dilution/change‑of‑control sensitivity; while this is company‑level, it can affect retention incentives and equity value realization for executives including Chuttani .